Report
Oliver Metzger

Gerresheimer AG : Q2 review – strong margin improvement, but guidance unchanged

>Continued double-digit top line momentum - The company reported Q2 revenues of € 499.6m (+11.9% y-o-y), 2% ahead of our forecast and the consensus. Organic growth was 12.8% compared to our 12.2% and the consensus’ 12.6%. Primary packaging glass grew organically by 9.2% in the quarter, while plastics & devices was up by 16.7%. The advanced technologies division generated revenues of € 2.4m, slightly lower than expected.Margin improvement to come through - ...
Underlying
Gerresheimer AG

Gerresheimer is a holding company. Through its subsidiaries, Co. manufactures glass and plastic products for the pharma and healthcare industry. Co.'s operates in three divisions: Plastics & Devices, which its product portfolio includes products for the administration of medicines, such as insulin pens, inhalers, and prefillable syringes; Primary Packaging Glass, which produces glass primary packaging for medicines and cosmetics, such as pharma jars, ampoules, injection vials, cartridges, perfume flacons, and cream jars; and Life Science Research, which produces laboratory glassware for research, development, and analytics, such as beakers, Erlenmeyer flasks, and measuring cylinders.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Oliver Metzger

Other Reports on these Companies
Other Reports from Oddo BHF

ResearchPool Subscriptions

Get the most out of your insights

Get in touch